Alvotech今日宣布，已与Lotus Pharmaceutical签署一项许可与商业化协议。该协议聚焦于两款拟议中的生物类似药——Durvalumab与Emicizumab，其市场覆盖范围包括美国及部分亚洲地区。
此项合作标志着Alvotech在扩大其全球生物类似药管线方面迈出关键一步。根据协议条款，Lotus Pharmaceutical将负责上述产品在指定区域内的商业化推广，而Alvotech则继续主导研发与生产环节。
通过携手Lotus Pharmaceutical，Alvotech旨在利用其合作伙伴在亚洲市场的深厚根基与商业化网络，加速这些潜在疗法的市场渗透。此举不仅有望提升患者对关键生物制剂的获取便利性，也反映出两家公司对满足未竟医疗需求的共同承诺。
协议的达成，进一步巩固了Alvotech作为生物类似药领域先行者的行业地位，同时也为Lotus Pharmaceutical拓宽其高价值产品组合提供了契机。随着全球对可负担生物药需求的持续攀升，此类合作的价值正愈发凸显。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.